Back

Sestrin2 protects against pressure overload–induced pathological cardiac hypertrophy via ULK1

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiac hypertrophy and pressure overload Cardiac Hypertrophy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Tao Liu

(China)

6 More presentations in this session

Presentation thumbnail
Endothelial redox signalling safeguards metabolic and transcriptional integrity and blocks middle-age cardiac hypertrophy
Ms M. Drekolia (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Ketone bodies independently of metabolic pathway attenuate cardiac hypertrophy through β-hydroxybutyrylation
Doctor J. Du (Chengdu, CN)
Abstract Slides
Presentation thumbnail
The Role of Neuropeptide Y in Human Cardiac Hypertrophy after Myocardial Infarction
Miss L. Ganzer (GB)
Abstract Slides
Presentation thumbnail
A porcine model of pressure overload–induced cardiac hypertrophy via catheter-based aortic stent implantation for aav-mediated gene therapy studies
Ms M. Corsten (Munich, DE)
Presentation thumbnail
Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy
Doctor M. Ernst (Vienna, AT)
Abstract Slides

Access the full session

Session thumbnail
Cardiac hypertrophy and pressure overload

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
CircMboat2 activates chaperone-mediated autophagy to promote the reversal of myocardial hypertrophy after pressure unloading of the left ventricle
1 September 2025
thumbnail
Congress Presentation
Phosphorylation of the essential myosin light chain by NIMA related kinase 9 is essential for systolic heart function
20 May 2023
thumbnail
Congress Presentation
Loss of smooth muscle SDF-1/CXCL12 leads to cardiac hypertrophy and aortic valve stenosis
30 August 2020
thumbnail
Congress Presentation
Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources